title: [Study on liver damage caused by anti-TB drug intermittent treatment on patients with HBV-TB co-infection].
abstract: OBJECTIVE
  To study the features of liver damage caused by anti-TB medicines among patients with TB-HBV co-infection, in order to complement and improve the implementation of DOTs strategy in the region.
  
  
  METHODS
  A historical cohort study was conducted including the process of reviewing and analyzing files of the 781 naive TB patients hospitalized from June 2004 to October 2005. Cases were divided into HBsAg (+) group and HBsAg (-) group.
  
  
  RESULTS
  The overall damage rate among the 781 investigation cases was 20.74%, including 121 cases (74.69%) in HBsAg (+) group and 41 cases (25.31%) in HBsAg (-) group. Data showed that liver damage rate and average value of ALT and AST of HBsAg (+) group were higher than those in HBsAg (-) group. First case with liver damage in HBsAg (+) group happened on the 7th day of the treatment, while the first liver damage case happened in HBsAg (-) group was on the 16th day. The average onset in HBsAg (+) group was earlier than HBsAg (-) group for 18.09 days. The average time of liver function recovery in HBsAg (+) group was 57.02 days and in HBsAg (-) group it was 27.56 days while the appearance among HBsAg (+) group was 29.46 days later than in HBsAg (-) group.
  
  
  CONCLUSIONS
  The incidence rate of liver damage caused by anti-TB medicines was higher among HBV positive patients than those HBV negative patients. Patients co-infected with HBV infection appeared to be more serious, with higher incidence on liver damage and earlier onset, as well as with the degree of damage to the liver.
authors.affiliation: Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning 530028, China.
authors.forename: Li-Hua
authors.initials: LH
authors.lastname: Huang
authors.forename: Wen-Kui
authors.initials: WK
authors.lastname: Geng
authors.forename: Jing
authors.initials: J
authors.lastname: Zhang
authors.forename: Ding-Wen
authors.initials: DW
authors.lastname: Lin
authors.forename: Fang
authors.initials: F
authors.lastname: Dong
authors.forename: Li-Sha
authors.initials: LS
authors.lastname: Zhou
authors.forename: Yi-Rong
authors.initials: YR
authors.lastname: Dong
authors.forename: Xue-Wen
authors.initials: XW
authors.lastname: Zhang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury; D005260:Female; D006509:Hepatitis B / Q000139:chemically induced / Q000150:complications / Q000453:epidemiology; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006801:Humans; D015994:Incidence; D008099:Liver / Q000473:pathology; D008107:Liver Diseases / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000188:drug therapy / Q000821:virology*; D055815:Young Adult
chemical_list: D000995:Antitubercular Agents; D006514:Hepatitis B Surface Antigens